Diabetes Drugs Market by Product, Application, Distribution Channel - Global Forecast 2025-2030- Product Image

Sale

Diabetes Drugs Market by Product, Application, Distribution Channel - Global Forecast 2025-2030

Report
197 Pages
October 2024
Region: Global
360iResearch™
ID: 4989870

UP TO €692EUR$697USD£576GBP OFF until Dec 31^st 2024

The Diabetes Drugs Market grew from USD 69.12 billion in 2023 to USD 72.97 billion in 2024. It is expected to continue growing at a CAGR of 5.88%, reaching USD 103.18 billion by 2030.

The diabetes drugs market, crucial for managing one of the most widespread chronic conditions globally, encompasses insulin, oral hypoglycemics, GLP-1 agonists, and SGLT2 inhibitors. The need for these drugs is driven by increasing diabetes prevalence due to sedentary lifestyles and rising obesity rates, necessitating robust treatment options. They find application in hospitals, clinics, and home care settings, aiding in blood sugar regulation and improving patient quality of life. Key growth influencers include advancements in drug delivery systems, government initiatives promoting diabetes care, and increased healthcare expenditure. The burgeoning elderly population, prone to diabetes, further fuels market growth. Current opportunities lie in expanding access to biologics and biosimilars, particularly in emerging markets with rising healthcare infrastructures. Additionally, personalized medicine and digital health solutions like smart insulin pumps present vast untapped potential. However, market expansion faces limitations, such as high treatment costs, stringent regulatory approvals, and the side effects associated with some medications. Intense competition and patent expirations pose significant challenges to sustained growth. Innovation can thrive in areas such as developing dual-action drugs that cater to both type 1 and type 2 diabetes, enhancing the efficacy and safety of existing treatments, and exploring gene therapy for diabetes management. Research targeting gut microbiota influence on diabetes and the role of artificial intelligence in predictive diagnostics are promising fields. The market is dynamic and heavily impacted by continual technological and therapeutic advancements, demanding adaptability and innovation. Strategic collaboration among pharmaceutical companies, researchers, and healthcare providers is advised to leverage growth opportunities and mitigate challenges. By focusing on cost-effective solutions and patient-centered care models, businesses can effectively capture and expand their market presence in the diabetes drugs sector.

Understanding Market Dynamics in the Diabetes Drugs Market

The Diabetes Drugs Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.

Market Drivers
- Increasing prevalence of diabetes globally
- Government Initiatives and supportive health policies for diabetes
- Growing research and development activities for advanced drug formulations
Market Restraints
- High cost of diabetes medications and complexity of diabetes management
Market Opportunities
- Emerging collaborations among research labs and pharmaceutical companies
- Rising demand for personalized medicine among consumers
Market Challenges
- Stringent government approval procedures

Exploring Porter’s Five Forces for the Diabetes Drugs Market

Porter’s Five Forces framework further strengthens the insights of the Diabetes Drugs Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Diabetes Drugs Market

External macro-environmental factors deeply influence the performance of the Diabetes Drugs Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Diabetes Drugs Market

The Diabetes Drugs Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Diabetes Drugs Market

The Diabetes Drugs Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Diabetes Drugs Market

The Diabetes Drugs Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Diabetes Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astellas Pharma Inc., AstraZeneca PLC, Baxter International, Inc., Bayer AG, Biocon Limited, Bioton S.A., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, Eva Pharma, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Gulf Pharmaceutical Industries (Julphar), Johnson & Johnson Services, Inc., Lupin Limited, MannKind Corporation, Merck & Co., Inc., MJ Biopharm Pvt. Ltd., Novartis AG, Novo Nordisk A/S, Oramed Pharmaceuticals Inc., Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Tonghua Dongbao Pharmaceutical Co., Ltd., Viatris Inc., and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Diabetes Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
- Insulin
  - Intermediate-Acting Insulin
  - Long-Acting Insulin
  - Premixed Insulin
  - Rapid-Acting Insulin
  - Short-Acting Insulin
- Non-Insulin Injectable Drugs
  - Amylin Analogs
  - GLP-1 Receptor Agonists
- Oral Drug
  - Biguanides
  - DPP-4 inhibitors
  - SGLT-2 inhibitors
  - Sulfonylureas
  - Thiazolidinediones
Application
- Gestational Diabetes
- Type 1 Diabetes
- Type 2 Diabetes
Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

What is the current size of the market, and how is it expected to grow?
Which products, segments, and regions present the most attractive investment opportunities?
What are the prevailing technology trends and regulatory factors influencing the market?
How do top vendors rank regarding market share and competitive positioning?
What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
4. Market Overview

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of diabetes globally
5.1.1.2. Government Initiatives and supportive health policies for diabetes
5.1.1.3. Growing research and development activities for advanced drug formulations
5.1.2. Restraints
5.1.2.1. High cost of diabetes medications and complexity of diabetes management
5.1.3. Opportunities
5.1.3.1. Emerging collaborations among research labs and pharmaceutical companies
5.1.3.2. Rising demand for personalized medicine among consumers
5.1.4. Challenges
5.1.4.1. Stringent government approval procedures
5.2. Market Segmentation Analysis
5.2.1. Product: Rising demand for long-acting insulin drugs among consumers
5.2.2. Application: Increasing application for treatment of type 2 diabetes
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental

6. Diabetes Drugs Market, by Product

6.1. Introduction
6.2. Insulin
6.2.1. Intermediate-Acting Insulin
6.2.2. Long-Acting Insulin
6.2.3. Premixed Insulin
6.2.4. Rapid-Acting Insulin
6.2.5. Short-Acting Insulin
6.3. Non-Insulin Injectable Drugs
6.3.1. Amylin Analogs
6.3.2. GLP-1 Receptor Agonists
6.4. Oral Drug
6.4.1. Biguanides
6.4.2. DPP-4 inhibitors
6.4.3. SGLT-2 inhibitors
6.4.4. Sulfonylureas
6.4.5. Thiazolidinediones

7. Diabetes Drugs Market, by Application

7.1. Introduction
7.2. Gestational Diabetes
7.3. Type 1 Diabetes
7.4. Type 2 Diabetes

8. Diabetes Drugs Market, by Distribution Channel

8.1. Introduction
8.2. Hospital Pharmacies
8.3. Online Pharmacies
8.4. Retail Pharmacies

9. Americas Diabetes Drugs Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Diabetes Drugs Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Diabetes Drugs Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.3.1. Eli Lilly gains approval for diabetes drug Tirzepatide in China
12.3.2. Sanofi India launches Soliqua for Type 2 diabetes and obesity, aiming to simplify treatment and improve compliance
12.3.3. Lupin secures USFDA approval for a generic diabetes drug, targets USD 5 million annual US market with competitive pricing and strategic expansion
12.4. Strategy Analysis & Recommendation

List of Figures

FIGURE 1. DIABETES DRUGS MARKET RESEARCH PROCESS
FIGURE 2. DIABETES DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL DIABETES DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL DIABETES DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 7. GLOBAL DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 11. GLOBAL DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. AMERICAS DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 13. AMERICAS DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. UNITED STATES DIABETES DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 15. UNITED STATES DIABETES DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. DIABETES DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 21. DIABETES DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

List of Tables

TABLE 1. DIABETES DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL DIABETES DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DIABETES DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. DIABETES DRUGS MARKET DYNAMICS
TABLE 7. GLOBAL DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DIABETES DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DIABETES DRUGS MARKET SIZE, BY INTERMEDIATE-ACTING INSULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DIABETES DRUGS MARKET SIZE, BY LONG-ACTING INSULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DIABETES DRUGS MARKET SIZE, BY PREMIXED INSULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DIABETES DRUGS MARKET SIZE, BY RAPID-ACTING INSULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DIABETES DRUGS MARKET SIZE, BY SHORT-ACTING INSULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DIABETES DRUGS MARKET SIZE, BY AMYLIN ANALOGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DIABETES DRUGS MARKET SIZE, BY SGLT-2 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DIABETES DRUGS MARKET SIZE, BY GESTATIONAL DIABETES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DIABETES DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DIABETES DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DIABETES DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 42. ARGENTINA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 46. ARGENTINA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 47. BRAZIL DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 48. BRAZIL DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 52. BRAZIL DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 53. CANADA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 54. CANADA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 55. CANADA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 56. CANADA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
TABLE 57. CANADA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 58. CANADA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. MEXICO DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 60. MEXICO DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 61. MEXICO DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 62. MEXICO DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
TABLE 63. MEXICO DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 64. MEXICO DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES DIABETES DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 72. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 73. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 74. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
TABLE 76. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 77. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 78. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 79. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 80. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 81. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 82. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
TABLE 83. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 84. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. CHINA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 86. CHINA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 87. CHINA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 88. CHINA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
TABLE 89. CHINA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 90. CHINA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 91. INDIA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 92. INDIA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 93. INDIA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 94. INDIA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
TABLE 95. INDIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 96. INDIA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. INDONESIA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 98. INDONESIA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 99. INDONESIA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 100. INDONESIA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
TABLE 101. INDONESIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 102. INDONESIA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. JAPAN DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 104. JAPAN DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 105. JAPAN DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 106. JAPAN DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
TABLE 107. JAPAN DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 108. JAPAN DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. MALAYSIA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 110. MALAYSIA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 111. MALAYSIA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 112. MALAYSIA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
TABLE 113. MALAYSIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 114. MALAYSIA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 115. PHILIPPINES DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 116. PHILIPPINES DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 117. PHILIPPINES DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 118. PHILIPPINES DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
TABLE 119. PHILIPPINES DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 120. PHILIPPINES DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 121. SINGAPORE DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 122. SINGAPORE DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 123. SINGAPORE DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 124. SINGAPORE DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
TABLE 125. SINGAPORE DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 126. SINGAPORE DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 127. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 128. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 129. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 130. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
TABLE 131. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 132. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 133. TAIWAN DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 134. TAIWAN DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 135. TAIWAN DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 136. TAIWAN DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
TABLE 137. TAIWAN DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 138. TAIWAN DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 139. THAILAND DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 140. THAILAND DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 141. THAILAND DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 142. THAILAND DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
TABLE 143. THAILAND DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 144. THAILAND DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. VIETNAM DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 146. VIETNAM DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 147. VIETNAM DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 148. VIETNAM DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
TABLE 149. VIETNAM DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 150. VIETNAM DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 158. DENMARK DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 159. DENMARK DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 160. DENMARK DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 161. DENMARK DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
TABLE 162. DENMARK DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 163. DENMARK DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 164. EGYPT DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 165. EGYPT DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 166. EGYPT DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 167. EGYPT DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
TABLE 168. EGYPT DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 169. EGYPT DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. FINLAND DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 171. FINLAND DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 172. FINLAND DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 173. FINLAND DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
TABLE 174. FINLAND DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 175. FINLAND DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 176. FRANCE DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 177. FRANCE DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 178. FRANCE DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 179. FRANCE DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
TABLE 180. FRANCE DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 181. FRANCE DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. GERMANY DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 183. GERMANY DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 184. GERMANY DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 185. GERMANY DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
TABLE 186. GERMANY DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 187. GERMANY DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 188. ISRAEL DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 189. ISRAEL DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 190. ISRAEL DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 191. ISRAEL DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
TABLE 192. ISRAEL DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 193. ISRAEL DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 194. ITALY DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 195. ITALY DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 196. ITALY DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 197. ITALY DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
TABLE 198. ITALY DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 199. ITALY DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 205. NETHERLANDS DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 206. NIGERIA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 207. NIGERIA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 212. NORWAY DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 213. NORWAY DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 214. NORWAY DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 215. NORWAY DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
TABLE 216. NORWAY DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 217. NORWAY DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 218. POLAND DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 219. POLAND DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 220. POLAND DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 221. POLAND DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
TABLE 222. POLAND DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 223. POLAND DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 224. QATAR DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 225. QATAR DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 226. QATAR DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 227. QATAR DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
TABLE 228. QATAR DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 229. QATAR DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 230. RUSSIA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 231. RUSSIA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 232. RUSSIA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 233. RUSSIA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
TABLE 234. RUSSIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 235. RUSSIA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 236. SAUDI ARABIA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 238. SAUDI ARABIA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
TABLE 240. SAUDI ARABIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 242. SOUTH AFRICA DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 244. SOUTH AFRICA DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
TABLE 246. SOUTH AFRICA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 248. SPAIN DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 249. SPAIN DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 250. SPAIN DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 251. SPAIN DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
TABLE 252. SPAIN DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 253. SPAIN DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
TABLE 258. SWEDEN DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 259. SWEDEN DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
TABLE 264. SWITZERLAND DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 265. SWITZERLAND DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 266. TURKEY DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 267. TURKEY DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 268. TURKEY DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 269. TURKEY DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
TABLE 270. TURKEY DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 271. TURKEY DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 272. UNITED ARAB EMIRATES DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 273. UNITED ARAB EMIRATES DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 278. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 279. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 280. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY NON-INSULIN INJECTABLE DRUGS, 2018-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
TABLE 282. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 283. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 284. DIABETES DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 285. DIABETES DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Diabetes Drugs Market, which are profiled in this report, include:

Abbott Laboratories
Astellas Pharma Inc.
AstraZeneca PLC
Baxter International, Inc.
Bayer AG
Biocon Limited
Bioton S.A.
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Company
Eli Lilly and Company
Eva Pharma
GlaxoSmithKline PLC
Glenmark Pharmaceuticals Limited
Gulf Pharmaceutical Industries (Julphar)
Johnson & Johnson Services, Inc.
Lupin Limited
MannKind Corporation
Merck & Co., Inc.
MJ Biopharm Pvt. Ltd.
Novartis AG
Novo Nordisk A/S
Oramed Pharmaceuticals Inc.
Pfizer Inc.
Sanofi S.A.
Takeda Pharmaceutical Company Limited
Tonghua Dongbao Pharmaceutical Co., Ltd.
Viatris Inc.
Zydus Lifesciences Limited

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	197
Published	October 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 72.97 Billion
Forecasted Market Value ( USD ) by 2030	$ 103.18 Billion
Compound Annual Growth Rate	5.8%
Regions Covered	Global
No. of Companies Mentioned	29

License	Format	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access		This is a single user license, allowing one user access to the product.	€3522EUR$3,545USD£2,928GBP €3913EUR$3,939USD£3,254GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€6231EUR$6,272USD£5,181GBP €6923EUR$6,969USD£5,757GBP

Understanding Market Dynamics in the Diabetes Drugs Market

Exploring Porter’s Five Forces for the Diabetes Drugs Market

Applying PESTLE Analysis to the Diabetes Drugs Market

Analyzing Market Share in the Diabetes Drugs Market

Evaluating Vendor Success with the FPNV Positioning Matrix in the Diabetes Drugs Market

Strategic Recommendations for Success in the Diabetes Drugs Market

Key Company Profiles

Market Segmentation & Coverage

The report provides a detailed overview of the market, exploring several key areas:

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

North America Diabetes Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2023 - 2028)

Asia-Pacific Diabetes Care Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2018 - 2029

Diabetes Drugs - Global Strategic Business Report

Type 2 Diabetes Drugs Market by Drug, Application, Distribution - Global Forecast 2025-2030

Type 1 Diabetes Drug Market by Form, End User - Global Forecast 2025-2030

About the Diabetes Drugs Market